IBDEI0N8 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10339,0)
 ;;=H25.12^^74^677^9
 ;;^UTILITY(U,$J,358.3,10339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10339,1,3,0)
 ;;=3^Cataract,Nuclear Age-Rel,Left Eye
 ;;^UTILITY(U,$J,358.3,10339,1,4,0)
 ;;=4^H25.12
 ;;^UTILITY(U,$J,358.3,10339,2)
 ;;=^5005285
 ;;^UTILITY(U,$J,358.3,10340,0)
 ;;=Z98.49^^74^677^8
 ;;^UTILITY(U,$J,358.3,10340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10340,1,3,0)
 ;;=3^Cataract Extraction Status,Unspec Eye
 ;;^UTILITY(U,$J,358.3,10340,1,4,0)
 ;;=4^Z98.49
 ;;^UTILITY(U,$J,358.3,10340,2)
 ;;=^5063739
 ;;^UTILITY(U,$J,358.3,10341,0)
 ;;=H04.123^^74^677^23
 ;;^UTILITY(U,$J,358.3,10341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10341,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,10341,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,10341,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,10342,0)
 ;;=H01.009^^74^677^6
 ;;^UTILITY(U,$J,358.3,10342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10342,1,3,0)
 ;;=3^Blepharitis,Unspec
 ;;^UTILITY(U,$J,358.3,10342,1,4,0)
 ;;=4^H01.009
 ;;^UTILITY(U,$J,358.3,10342,2)
 ;;=^5133381
 ;;^UTILITY(U,$J,358.3,10343,0)
 ;;=H40.023^^74^677^31
 ;;^UTILITY(U,$J,358.3,10343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10343,1,3,0)
 ;;=3^Glaucoma Suspect,High Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,10343,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,10343,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,10344,0)
 ;;=H40.053^^74^677^42
 ;;^UTILITY(U,$J,358.3,10344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10344,1,3,0)
 ;;=3^Ocular Hypertension,Bilateral
 ;;^UTILITY(U,$J,358.3,10344,1,4,0)
 ;;=4^H40.053
 ;;^UTILITY(U,$J,358.3,10344,2)
 ;;=^5005742
 ;;^UTILITY(U,$J,358.3,10345,0)
 ;;=E11.9^^74^677^20
 ;;^UTILITY(U,$J,358.3,10345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10345,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,10345,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,10345,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,10346,0)
 ;;=E11.39^^74^677^19
 ;;^UTILITY(U,$J,358.3,10346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10346,1,3,0)
 ;;=3^DM Type 2 w/ Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,10346,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,10346,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,10347,0)
 ;;=H59.039^^74^677^7
 ;;^UTILITY(U,$J,358.3,10347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10347,1,3,0)
 ;;=3^CME Mac Edema,Unspec Eye
 ;;^UTILITY(U,$J,358.3,10347,1,4,0)
 ;;=4^H59.039
 ;;^UTILITY(U,$J,358.3,10347,2)
 ;;=^5006396
 ;;^UTILITY(U,$J,358.3,10348,0)
 ;;=H43.391^^74^677^55
 ;;^UTILITY(U,$J,358.3,10348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10348,1,3,0)
 ;;=3^Vitreous Opacities,Right Eye NEC
 ;;^UTILITY(U,$J,358.3,10348,1,4,0)
 ;;=4^H43.391
 ;;^UTILITY(U,$J,358.3,10348,2)
 ;;=^5005949
 ;;^UTILITY(U,$J,358.3,10349,0)
 ;;=H43.392^^74^677^54
 ;;^UTILITY(U,$J,358.3,10349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10349,1,3,0)
 ;;=3^Vitreous Opacities,Left Eye NEC
 ;;^UTILITY(U,$J,358.3,10349,1,4,0)
 ;;=4^H43.392
 ;;^UTILITY(U,$J,358.3,10349,2)
 ;;=^5005950
 ;;^UTILITY(U,$J,358.3,10350,0)
 ;;=H02.831^^74^677^22
 ;;^UTILITY(U,$J,358.3,10350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10350,1,3,0)
 ;;=3^Dermatochalasis,Right Upper Eyelid
 ;;^UTILITY(U,$J,358.3,10350,1,4,0)
 ;;=4^H02.831
 ;;^UTILITY(U,$J,358.3,10350,2)
 ;;=^5004418
 ;;^UTILITY(U,$J,358.3,10351,0)
 ;;=H02.834^^74^677^21
 ;;^UTILITY(U,$J,358.3,10351,1,0)
 ;;=^358.31IA^4^2
